Pelvic lymph node dissection in prostate cancer staging: evaluation of morbidity and oncological outcomes

References

• Briganti A, Blute ML, Eastham JH, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol. 2009;55:1251–1265.
   PubMed Web of Science ®Google Scholar
• Abdollah F, Suardi N, Gallina A, et al. Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center. Ann Oncol. 2013;24:1459–1466.
   PubMedGoogle Scholar
• Roach M, 3rd, Marquez C, Yuo HS, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;28:33–37.
   PubMed Web of Science ®Google Scholar
• Godoy G, Chong KT, Cronin A, et al. Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. Eur Urol. 2011;60:195–201.
   PubMed Web of Science ®Google Scholar
• Briganti A, Chun FK, Salonia A, et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol. 2006;50:1006–1013.
   PubMed Web of Science ®Google Scholar
• Ploussard G, Briganti A, de la Taille A, et al. Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature. Eur Urol. 2014;65:7–16.
   PubMed Web of Science ®Google Scholar
• Schiavina R, Manferrari F, Garofalo M, et al. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer. Bju International. 2011;108:1262–1268.
   PubMed Web of Science ®Google Scholar
• Masterson TA, Bianco FJ, Jr., Vickers AJ, et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol. 2006;175:1320–1324. discussion 4-5.
   PubMed Web of Science ®Google Scholar
• Moschini M, Fossati N, Abdollah F, et al. Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection. Prostate Cancer Prostatic Dis. 2016;19:63–67.
   PubMed Web of Science ®Google Scholar
• Murphy AM, Berkman DS, Desai M, et al. The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy. BJU Int. 2010;105:176–179.
   PubMed Web of Science ®Google Scholar
• Truesdale MD, Lee DJ, Cheetham PJ, et al. Assessment of lymph node yield after pelvic lymph node dissection in men with prostate cancer: a comparison between robot-assisted radical prostatectomy and open radical prostatectomy in the modern era. J Endourol. 2010;24:1055–1060.
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Trinh QD, Hu JC, et al. The impact of robot-assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the “post-dissemination” period. Eur J Surg Oncol. 2014;40:1080–1086.
   PubMed Web of Science ®Google Scholar
• Yuh BE, Ruel NH, Mejia R, et al. Standardized comparison of robot-assisted limited and extended pelvic lymphadenectomy for prostate cancer. BJU Int. 2013;112:81–88.
   PubMed Web of Science ®Google Scholar
• Eden CG, Zacharakis E, Bott S. The learning curve for laparoscopic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer: implications for compliance with existing guidelines. BJU Int. 2013;112:346–354.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol. 2007;52:29–37.
   PubMed Web of Science ®Google Scholar
• Danuser H, Di Pierro GB, Stucki P, et al. Extended pelvic lymphadenectomy and various radical prostatectomy techniques: is pelvic drainage necessary? BJU Int. 2013;111:963–969.
   PubMed Web of Science ®Google Scholar
• Hall WH, Jani AB, Ryu JK, et al. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis. 2005;8:22–30.
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Whittington R, Koo S, et al. The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma. Cancer. 2005;103:2053–2059.
   PubMed Web of Science ®Google Scholar
• Poelaert F, Fonteyne V, Ost P, et al. Whole pelvis radiotherapy for pathological node-positive prostate cancer. Strahlenther Onkol. 2017;193:444–451.
   PubMed Web of Science ®Google Scholar
• Briganti A, Karnes JR, Da Pozzo LF, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N + patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol. 2009;55:261–270.
   PubMed Web of Science ®Google Scholar
• DiMarco DS, Zincke H, Sebo TJ, et al. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol. 2005;173:1121–1125.
   PubMedGoogle Scholar
• Simonato A, Varca V, Esposito M, et al. The use of a surgical patch in the prevention of lymphoceles after extraperitoneal pelvic lymphadenectomy for prostate cancer: a randomized prospective pilot study. J Urol. 2009;182:2285–2290.
   PubMed Web of Science ®Google Scholar